Early test results for U.S. drug ‘one of the biggest breakthroughs’ for cancer, says Canadian oncologist
Summary
- U.S. drugmaker Erasca reported that its experimental pill ERAS-0015 reduced tumors in 44% of 25 patients with advanced pancreatic cancer & 60% of 5 lung cancer patients in an early-stage trial.
- 69% of patients with the two most common genetic variations of pancreatic cancer showed positive results after taking a 32 mg daily dose of the drug.
- Erasca plans to begin late-stage clinical trials for ERAS-0015 & another treatment called ERAS-4001 in 2027.
- Dr. Jennifer Knox of Toronto's Princess Margaret Cancer Centre will supervise patient trials in Canada next year & described the findings as a major breakthrough for pancreatic cancer.
- The drug targets the mutant RAS protein, which is present in roughly 95% of pancreatic cancers & drives cell growth when mutated.
- This development follows a similar breakthrough earlier this year involving daraxonrasib from Revolution Medicines, which doubled survival times for patients.
- Although generally well-tolerated, one patient previously died from lung inflammation while taking a 24 mg dose of the drug.
- Experts note that while the early trial results are promising, longer trials are required to determine if microscopic cancer cells remain & cause recurrence.
An experimental U.S. drug that saw positive results in patients during early tests is a major ‘breakthrough’ for cancer patients, Canadian doctors say.